APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ulcerative Colitis Immunology Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Ulcerative Colitis Immunology Drugs Market Outlook and Growth Opportunities 2026

19 December 2025199 pages

Choose your research edition.

Industry ResearchUlcerative Colitis Immunology Drugs Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Ulcerative Colitis Immunology Drugs Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Ulcerative Colitis Immunology Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ulcerative Colitis Immunology Drugs Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Ulcerative Colitis Immunology Drugs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Ulcerative Colitis Immunology Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Ulcerative Colitis Immunology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Ulcerative Colitis Immunology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Ulcerative Colitis Immunology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Ulcerative Colitis Immunology Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Ulcerative Colitis Immunology Drugs market include Bristol-Myers Squibb Company, Celltrion Healthcare, Genentech USA, Inc., UCBCares, AbbVie Inc., AMGEN, Biogen, Pfizer Inc. and ROCHE, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Ulcerative Colitis Immunology Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Ulcerative Colitis Immunology Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Ulcerative Colitis Immunology Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Ulcerative Colitis Immunology Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Ulcerative Colitis Immunology Drugs Segment by Company

Bristol-Myers Squibb Company

Celltrion Healthcare

Genentech USA, Inc.

UCBCares

AbbVie Inc.

AMGEN

Biogen

Pfizer Inc.

ROCHE

Janssen Biotech, Inc.

Ulcerative Colitis Immunology Drugs Segment by Type

Infliximab

Etanercept

Tofacitinib

Certolizumab Pegol

Golimumab

Adalimumab

Abatacept

Others

Ulcerative Colitis Immunology Drugs Segment by Application

Crohn's Disease(CD)

Ulcerative Colitis(UC)

Rheumatoid Arthritis

Ankylosing Spondylitis(AS)

Psoriasis(Ps)

Ulcerative Colitis Immunology Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Ulcerative Colitis Immunology Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Ulcerative Colitis Immunology Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Ulcerative Colitis Immunology Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Ulcerative Colitis Immunology Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ulcerative Colitis Immunology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ulcerative Colitis Immunology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ulcerative Colitis Immunology Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Ulcerative Colitis Immunology Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Ulcerative Colitis Immunology Drugs industry.

Chapter 3: Detailed analysis of Ulcerative Colitis Immunology Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Ulcerative Colitis Immunology Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Ulcerative Colitis Immunology Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Ulcerative Colitis Immunology Drugs Industry Trends Table 2. Ulcerative Colitis Immunology Drugs Industry Drivers Table 3. Ulcerative Colitis Immunology Drugs Industry Opportunities and Challenges Table 4. Ulcerative Colitis Immunology Drugs Industry Restraints Table 5. Global Ulcerative Colitis Immunology Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Ulcerative Colitis Immunology Drugs Revenue Share by Company (2021-2026) Table 7. Global Ulcerative Colitis Immunology Drugs Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Ulcerative Colitis Immunology Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Ulcerative Colitis Immunology Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Ulcerative Colitis Immunology Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Ulcerative Colitis Immunology Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Ulcerative Colitis Immunology Drugs Company, Product Type & Application Table 13. Global Ulcerative Colitis Immunology Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Ulcerative Colitis Immunology Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Infliximab Table 18. Significant Companies of Etanercept Table 19. Significant Companies of Tofacitinib Table 20. Significant Companies of Certolizumab Pegol Table 21. Significant Companies of Golimumab Table 22. Significant Companies of Adalimumab Table 23. Significant Companies of Abatacept Table 24. Significant Companies of Others Table 25. Global Ulcerative Colitis Immunology Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 26. Global Ulcerative Colitis Immunology Drugs Sales Volume by Type (2021-2026) & (W Units) Table 27. Global Ulcerative Colitis Immunology Drugs Sales Volume by Type (2027-2032) & (W Units) Table 28. Global Ulcerative Colitis Immunology Drugs Sales Volume Share by Type (2021-2026) Table 29. Global Ulcerative Colitis Immunology Drugs Sales Volume Share by Type (2027-2032) Table 30. Global Ulcerative Colitis Immunology Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Ulcerative Colitis Immunology Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 32. Global Ulcerative Colitis Immunology Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 33. Global Ulcerative Colitis Immunology Drugs Sales Value Share by Type (2021-2026) Table 34. Global Ulcerative Colitis Immunology Drugs Sales Value Share by Type (2027-2032) Table 35. Significant Companies of Crohn's Disease(CD) Table 36. Significant Companies of Ulcerative Colitis(UC) Table 37. Significant Companies of Rheumatoid Arthritis Table 38. Significant Companies of Ankylosing Spondylitis(AS) Table 39. Significant Companies of Psoriasis(Ps) Table 40. Global Ulcerative Colitis Immunology Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 41. Global Ulcerative Colitis Immunology Drugs Sales Volume by Application (2021-2026) & (W Units) Table 42. Global Ulcerative Colitis Immunology Drugs Sales Volume by Application (2027-2032) & (W Units) Table 43. Global Ulcerative Colitis Immunology Drugs Sales Volume Share by Application (2021-2026) Table 44. Global Ulcerative Colitis Immunology Drugs Sales Volume Share by Application (2027-2032) Table 45. Global Ulcerative Colitis Immunology Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Ulcerative Colitis Immunology Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 47. Global Ulcerative Colitis Immunology Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 48. Global Ulcerative Colitis Immunology Drugs Sales Value Share by Application (2021-2026) Table 49. Global Ulcerative Colitis Immunology Drugs Sales Value Share by Application (2027-2032) Table 50. Global Ulcerative Colitis Immunology Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 51. Global Ulcerative Colitis Immunology Drugs Sales by Region (2021-2026) & (W Units) Table 52. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Region (2021-2026) Table 53. Global Ulcerative Colitis Immunology Drugs Sales by Region (2027-2032) & (W Units) Table 54. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Region (2027-2032) Table 55. Global Ulcerative Colitis Immunology Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Ulcerative Colitis Immunology Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 57. Global Ulcerative Colitis Immunology Drugs Sales Value Share by Region (2021-2026) Table 58. Global Ulcerative Colitis Immunology Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 59. Global Ulcerative Colitis Immunology Drugs Sales Value Share by Region (2027-2032) Table 60. Global Ulcerative Colitis Immunology Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 61. Global Ulcerative Colitis Immunology Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 62. Global Ulcerative Colitis Immunology Drugs Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 63. Global Ulcerative Colitis Immunology Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Ulcerative Colitis Immunology Drugs Sales by Country (2021-2026) & (W Units) Table 65. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Country (2021-2026) Table 66. Global Ulcerative Colitis Immunology Drugs Sales by Country (2027-2032) & (W Units) Table 67. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Country (2027-2032) Table 68. Global Ulcerative Colitis Immunology Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 69. Global Ulcerative Colitis Immunology Drugs Sales Value Market Share by Country (2021-2026) Table 70. Global Ulcerative Colitis Immunology Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 71. Global Ulcerative Colitis Immunology Drugs Sales Value Market Share by Country (2027-2032) Table 72. Bristol-Myers Squibb Company Company Information Table 73. Bristol-Myers Squibb Company Business Overview Table 74. Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Product Portfolio Table 76. Bristol-Myers Squibb Company Recent Development Table 77. Celltrion Healthcare Company Information Table 78. Celltrion Healthcare Business Overview Table 79. Celltrion Healthcare Ulcerative Colitis Immunology Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Celltrion Healthcare Ulcerative Colitis Immunology Drugs Product Portfolio Table 81. Celltrion Healthcare Recent Development Table 82. Genentech USA, Inc. Company Information Table 83. Genentech USA, Inc. Business Overview Table 84. Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Product Portfolio Table 86. Genentech USA, Inc. Recent Development Table 87. UCBCares Company Information Table 88. UCBCares Business Overview Table 89. UCBCares Ulcerative Colitis Immunology Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. UCBCares Ulcerative Colitis Immunology Drugs Product Portfolio Table 91. UCBCares Recent Development Table 92. AbbVie Inc. Company Information Table 93. AbbVie Inc. Business Overview Table 94. AbbVie Inc. Ulcerative Colitis Immunology Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. AbbVie Inc. Ulcerative Colitis Immunology Drugs Product Portfolio Table 96. AbbVie Inc. Recent Development Table 97. AMGEN Company Information Table 98. AMGEN Business Overview Table 99. AMGEN Ulcerative Colitis Immunology Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. AMGEN Ulcerative Colitis Immunology Drugs Product Portfolio Table 101. AMGEN Recent Development Table 102. Biogen Company Information Table 103. Biogen Business Overview Table 104. Biogen Ulcerative Colitis Immunology Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Biogen Ulcerative Colitis Immunology Drugs Product Portfolio Table 106. Biogen Recent Development Table 107. Pfizer Inc. Company Information Table 108. Pfizer Inc. Business Overview Table 109. Pfizer Inc. Ulcerative Colitis Immunology Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Pfizer Inc. Ulcerative Colitis Immunology Drugs Product Portfolio Table 111. Pfizer Inc. Recent Development Table 112. ROCHE Company Information Table 113. ROCHE Business Overview Table 114. ROCHE Ulcerative Colitis Immunology Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. ROCHE Ulcerative Colitis Immunology Drugs Product Portfolio Table 116. ROCHE Recent Development Table 117. Janssen Biotech, Inc. Company Information Table 118. Janssen Biotech, Inc. Business Overview Table 119. Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Product Portfolio Table 121. Janssen Biotech, Inc. Recent Development Table 122. Key Raw Materials Table 123. Raw Materials Key Suppliers Table 124. Ulcerative Colitis Immunology Drugs Distributors List Table 125. Ulcerative Colitis Immunology Drugs Customers List Table 126. Research Programs/Design for This Report Table 127. Authors List of This Report Table 128. Secondary Sources Table 129. Primary Sources List of Figures Figure 1. Ulcerative Colitis Immunology Drugs Product Image Figure 2. Global Ulcerative Colitis Immunology Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ulcerative Colitis Immunology Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Ulcerative Colitis Immunology Drugs Sales (2021-2032) & (W Units) Figure 5. Global Ulcerative Colitis Immunology Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Ulcerative Colitis Immunology Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Infliximab Image Figure 10. Etanercept Image Figure 11. Tofacitinib Image Figure 12. Certolizumab Pegol Image Figure 13. Golimumab Image Figure 14. Adalimumab Image Figure 15. Abatacept Image Figure 16. Others Image Figure 17. Global Ulcerative Colitis Immunology Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 18. Global Ulcerative Colitis Immunology Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 19. Global Ulcerative Colitis Immunology Drugs Sales Volume Share by Type (2021-2032) Figure 20. Global Ulcerative Colitis Immunology Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Ulcerative Colitis Immunology Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 22. Global Ulcerative Colitis Immunology Drugs Sales Value Share by Type (2021-2032) Figure 23. Crohn's Disease(CD) Image Figure 24. Ulcerative Colitis(UC) Image Figure 25. Rheumatoid Arthritis Image Figure 26. Ankylosing Spondylitis(AS) Image Figure 27. Psoriasis(Ps) Image Figure 28. Global Ulcerative Colitis Immunology Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 29. Global Ulcerative Colitis Immunology Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 30. Global Ulcerative Colitis Immunology Drugs Sales Volume Share by Application (2021-2032) Figure 31. Global Ulcerative Colitis Immunology Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 32. Global Ulcerative Colitis Immunology Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 33. Global Ulcerative Colitis Immunology Drugs Sales Value Share by Application (2021-2032) Figure 34. Global Ulcerative Colitis Immunology Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 35. Global Ulcerative Colitis Immunology Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 36. Global Ulcerative Colitis Immunology Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 37. Global Ulcerative Colitis Immunology Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 38. North America Ulcerative Colitis Immunology Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. North America Ulcerative Colitis Immunology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Europe Ulcerative Colitis Immunology Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. Europe Ulcerative Colitis Immunology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales Value (2021-2032) & (US$ Million) Figure 43. Asia-Pacific Ulcerative Colitis Immunology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 44. South America Ulcerative Colitis Immunology Drugs Sales Value (2021-2032) & (US$ Million) Figure 45. South America Ulcerative Colitis Immunology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 46. Middle East & Africa Ulcerative Colitis Immunology Drugs Sales Value (2021-2032) & (US$ Million) Figure 47. Middle East & Africa Ulcerative Colitis Immunology Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 48. USA Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. USA Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. USA Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Canada Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Canada Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Canada Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Mexico Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Mexico Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Mexico Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Germany Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Germany Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Germany Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. France Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. France Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. France Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. U.K. Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. U.K. Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. U.K. Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Italy Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Italy Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Italy Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Spain Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Spain Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Spain Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Russia Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Russia Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Russia Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Netherlands Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Netherlands Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Netherlands Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Nordic Countries Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Nordic Countries Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Nordic Countries Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. China Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. China Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. China Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Japan Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Japan Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Japan Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. South Korea Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. South Korea Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. South Korea Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. India Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. India Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. India Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Australia Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Australia Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Australia Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Southeast Asia Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Southeast Asia Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Southeast Asia Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Brazil Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Brazil Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Brazil Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Argentina Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Argentina Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Argentina Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Chile Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Chile Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Chile Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Colombia Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Colombia Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Colombia Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Peru Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Peru Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Peru Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Saudi Arabia Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Saudi Arabia Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Saudi Arabia Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Israel Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Israel Arabia Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Israel Arabia Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. UAE Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. UAE Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. UAE Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Turkey Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Turkey Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Turkey Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Iran Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Iran Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Iran Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Egypt Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 130. Egypt Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 131. Egypt Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 132. Ulcerative Colitis Immunology Drugs Value Chain Figure 133. Manufacturing Cost Structure Figure 134. Ulcerative Colitis Immunology Drugs Sales Mode & Process Figure 135. Direct Comparison with Distribution Share Figure 136. Distributors Profiles Figure 137. Years Considered Figure 138. Research Process Figure 139. Key Executives Interviewed

Scope & coverage.

Types
  • Infliximab
  • Etanercept
  • Tofacitinib
  • Certolizumab Pegol
  • Golimumab
  • Adalimumab
  • Abatacept
  • Others
Applications
  • Crohn's Disease(CD)
  • Ulcerative Colitis(UC)
  • Rheumatoid Arthritis
  • Ankylosing Spondylitis(AS)
  • Psoriasis(Ps)
Companies covered
  • Bristol-Myers Squibb Company
  • Celltrion Healthcare
  • Genentech USA, Inc.
  • UCBCares
  • AbbVie Inc.
  • AMGEN
  • Biogen
  • Pfizer Inc.
  • ROCHE
  • Janssen Biotech, Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Ulcerative Colitis Immunology Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Ulcerative Colitis Immunology Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Ulcerative Colitis Immunology Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Ulcerative Colitis Immunology Drugs Market Dynamics
  1. 2.1 Ulcerative Colitis Immunology Drugs Industry Trends
  2. 2.2 Ulcerative Colitis Immunology Drugs Industry Drivers
  3. 2.3 Ulcerative Colitis Immunology Drugs Industry Opportunities and Challenges
  4. 2.4 Ulcerative Colitis Immunology Drugs Industry Restraints
3 Ulcerative Colitis Immunology Drugs Market by Company
  1. 3.1 Global Ulcerative Colitis Immunology Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Ulcerative Colitis Immunology Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Ulcerative Colitis Immunology Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Ulcerative Colitis Immunology Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Ulcerative Colitis Immunology Drugs Company Ranking (2024-2026)
  6. 3.6 Global Ulcerative Colitis Immunology Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Ulcerative Colitis Immunology Drugs Company Product Type and Application
  8. 3.8 Global Ulcerative Colitis Immunology Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Ulcerative Colitis Immunology Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Ulcerative Colitis Immunology Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Ulcerative Colitis Immunology Drugs Market by Type
  1. 4.1 Ulcerative Colitis Immunology Drugs Type Introduction
  2. 4.1.1 Infliximab
  3. 4.1.2 Etanercept
  4. 4.1.3 Tofacitinib
  5. 4.1.4 Certolizumab Pegol
  6. 4.1.5 Golimumab
  7. 4.1.6 Adalimumab
  8. 4.1.7 Abatacept
  9. 4.1.8 Others
  10. 4.2 Global Ulcerative Colitis Immunology Drugs Sales Volume by Type
  11. 4.2.1 Global Ulcerative Colitis Immunology Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Ulcerative Colitis Immunology Drugs Sales Volume by Type (2021-2032)
  13. 4.2.3 Global Ulcerative Colitis Immunology Drugs Sales Volume Share by Type (2021-2032)
  14. 4.3 Global Ulcerative Colitis Immunology Drugs Sales Value by Type
  15. 4.3.1 Global Ulcerative Colitis Immunology Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global Ulcerative Colitis Immunology Drugs Sales Value by Type (2021-2032)
  17. 4.3.3 Global Ulcerative Colitis Immunology Drugs Sales Value Share by Type (2021-2032)
5 Ulcerative Colitis Immunology Drugs Market by Application
  1. 5.1 Ulcerative Colitis Immunology Drugs Application Introduction
  2. 5.1.1 Crohn's Disease(CD)
  3. 5.1.2 Ulcerative Colitis(UC)
  4. 5.1.3 Rheumatoid Arthritis
  5. 5.1.4 Ankylosing Spondylitis(AS)
  6. 5.1.5 Psoriasis(Ps)
  7. 5.2 Global Ulcerative Colitis Immunology Drugs Sales Volume by Application
  8. 5.2.1 Global Ulcerative Colitis Immunology Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Ulcerative Colitis Immunology Drugs Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Ulcerative Colitis Immunology Drugs Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Ulcerative Colitis Immunology Drugs Sales Value by Application
  12. 5.3.1 Global Ulcerative Colitis Immunology Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Ulcerative Colitis Immunology Drugs Sales Value by Application (2021-2032)
  14. 5.3.3 Global Ulcerative Colitis Immunology Drugs Sales Value Share by Application (2021-2032)
6 Ulcerative Colitis Immunology Drugs Regional Sales and Value Analysis
  1. 6.1 Global Ulcerative Colitis Immunology Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Ulcerative Colitis Immunology Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Ulcerative Colitis Immunology Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Ulcerative Colitis Immunology Drugs Sales by Region (2027-2032)
  5. 6.3 Global Ulcerative Colitis Immunology Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Ulcerative Colitis Immunology Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Ulcerative Colitis Immunology Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Ulcerative Colitis Immunology Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Ulcerative Colitis Immunology Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Ulcerative Colitis Immunology Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Ulcerative Colitis Immunology Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Ulcerative Colitis Immunology Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Ulcerative Colitis Immunology Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Ulcerative Colitis Immunology Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Ulcerative Colitis Immunology Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Ulcerative Colitis Immunology Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Ulcerative Colitis Immunology Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Ulcerative Colitis Immunology Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Ulcerative Colitis Immunology Drugs Sales Value Share by Country, 2025 VS 2032
7 Ulcerative Colitis Immunology Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Ulcerative Colitis Immunology Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Ulcerative Colitis Immunology Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Ulcerative Colitis Immunology Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Ulcerative Colitis Immunology Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Ulcerative Colitis Immunology Drugs Sales by Country (2027-2032)
  6. 7.4 Global Ulcerative Colitis Immunology Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Ulcerative Colitis Immunology Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Ulcerative Colitis Immunology Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Ulcerative Colitis Immunology Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Ulcerative Colitis Immunology Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Ulcerative Colitis Immunology Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bristol-Myers Squibb Company
  2. 8.1.1 Bristol-Myers Squibb Company Company Information
  3. 8.1.2 Bristol-Myers Squibb Company Business Overview
  4. 8.1.3 Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bristol-Myers Squibb Company Ulcerative Colitis Immunology Drugs Product Portfolio
  6. 8.1.5 Bristol-Myers Squibb Company Recent Developments
  7. 8.2 Celltrion Healthcare
  8. 8.2.1 Celltrion Healthcare Company Information
  9. 8.2.2 Celltrion Healthcare Business Overview
  10. 8.2.3 Celltrion Healthcare Ulcerative Colitis Immunology Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Celltrion Healthcare Ulcerative Colitis Immunology Drugs Product Portfolio
  12. 8.2.5 Celltrion Healthcare Recent Developments
  13. 8.3 Genentech USA, Inc.
  14. 8.3.1 Genentech USA, Inc. Company Information
  15. 8.3.2 Genentech USA, Inc. Business Overview
  16. 8.3.3 Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Genentech USA, Inc. Ulcerative Colitis Immunology Drugs Product Portfolio
  18. 8.3.5 Genentech USA, Inc. Recent Developments
  19. 8.4 UCBCares
  20. 8.4.1 UCBCares Company Information
  21. 8.4.2 UCBCares Business Overview
  22. 8.4.3 UCBCares Ulcerative Colitis Immunology Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 UCBCares Ulcerative Colitis Immunology Drugs Product Portfolio
  24. 8.4.5 UCBCares Recent Developments
  25. 8.5 AbbVie Inc.
  26. 8.5.1 AbbVie Inc. Company Information
  27. 8.5.2 AbbVie Inc. Business Overview
  28. 8.5.3 AbbVie Inc. Ulcerative Colitis Immunology Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AbbVie Inc. Ulcerative Colitis Immunology Drugs Product Portfolio
  30. 8.5.5 AbbVie Inc. Recent Developments
  31. 8.6 AMGEN
  32. 8.6.1 AMGEN Company Information
  33. 8.6.2 AMGEN Business Overview
  34. 8.6.3 AMGEN Ulcerative Colitis Immunology Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AMGEN Ulcerative Colitis Immunology Drugs Product Portfolio
  36. 8.6.5 AMGEN Recent Developments
  37. 8.7 Biogen
  38. 8.7.1 Biogen Company Information
  39. 8.7.2 Biogen Business Overview
  40. 8.7.3 Biogen Ulcerative Colitis Immunology Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Biogen Ulcerative Colitis Immunology Drugs Product Portfolio
  42. 8.7.5 Biogen Recent Developments
  43. 8.8 Pfizer Inc.
  44. 8.8.1 Pfizer Inc. Company Information
  45. 8.8.2 Pfizer Inc. Business Overview
  46. 8.8.3 Pfizer Inc. Ulcerative Colitis Immunology Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Inc. Ulcerative Colitis Immunology Drugs Product Portfolio
  48. 8.8.5 Pfizer Inc. Recent Developments
  49. 8.9 ROCHE
  50. 8.9.1 ROCHE Company Information
  51. 8.9.2 ROCHE Business Overview
  52. 8.9.3 ROCHE Ulcerative Colitis Immunology Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 ROCHE Ulcerative Colitis Immunology Drugs Product Portfolio
  54. 8.9.5 ROCHE Recent Developments
  55. 8.10 Janssen Biotech, Inc.
  56. 8.10.1 Janssen Biotech, Inc. Company Information
  57. 8.10.2 Janssen Biotech, Inc. Business Overview
  58. 8.10.3 Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Janssen Biotech, Inc. Ulcerative Colitis Immunology Drugs Product Portfolio
  60. 8.10.5 Janssen Biotech, Inc. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Ulcerative Colitis Immunology Drugs Value Chain Analysis
  2. 9.1.1 Ulcerative Colitis Immunology Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Ulcerative Colitis Immunology Drugs Sales Mode & Process
  6. 9.2 Ulcerative Colitis Immunology Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Ulcerative Colitis Immunology Drugs Distributors
  9. 9.2.3 Ulcerative Colitis Immunology Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst